Innate Pharma S.A.
IPHA • Biotechnology
$2.08
▼ -0.03 (-1.42%)
Current price
EarningsLatest report: Dec 31, 2025
WEAK PROFILEWeakConfidence: 70%
Quantitative profile — not an investment recommendation.
Quantitative profile — not an investment recommendation.Methodology
Analysis thesis: Weak historical ratio profile. The current evidence does not support a favorable risk/reward view.
Market Cap
$169.96M
Growth
-5.0%
Cash Flow
0/5
Trend
Negative
Evidence
Negative growth trendWeak profitability
Financial data as of: Dec 31, 2025, 12:00 AM UTCLast earnings update: Dec 31, 2025, 12:00 AM UTCLast profile update: Aug 5, 2026, 2:27 PM UTC
Company Snapshot
Key valuation, quality, financial strength, momentum and analyst data.
Price$2.08
Change-1.42%
Market Cap$169.96M
52W Range1.17 - 2.63
Beta0.89
Gross Margin100.00%
Oper. Margin-19.17%
Profit Margin-17.65%
Debt/Eq-1.04
Current Ratio1.27
Quick Ratio1.27
Revenue 5Y-5.02%
Price$2.08
Change-1.42%
Market Cap$169.96M
52W Range1.17 - 2.63
Beta0.89
Gross Margin100.00%
Oper. Margin-19.17%
Profit Margin-17.65%
Debt/Eq-1.04
Current Ratio1.27
Quick Ratio1.27
Revenue 5Y-5.02%
Target$3.50
Target Upside68.27%
Target Median$3.50
Target Range2.00 - 5.00
Volume8.74K
Avg Volume74.70K
EPS Surprise-0.19
Investment DNA
How strong this company looks for long-term investors
26
out of 100
Business Quality
Margins, moat, returns
22/100
Financial Strength
Debt, cash, stability
57/100
Growth Potential
Revenue and expansion
20/100
Price Attractiveness
Cheap or expensive today
20/100
Why this score▼
Negative growth trendWeak profitability
Analyst view
Analyst sentiment and price target
Analyst sentiment
No vote count available
Bullish
0
Hold
0
Bearish
0
Price Target
2026-06-23
Low
$2.00
Mean
$3.50
Median
$3.50
High
$5.00
🧾
No insider activity
No recent insider transactions available.